Bacteroides fragilis is an important etiological agent of serious infections in humans. Rapid methods, readily adaptable to use in medical laboratories, are needed to detect antibiotic resistance and decrease the likelihood of therapy failure. The aim of this study was to determine the prevalence of B. fragilis cfiA-positive isolates. The second purpose was to investigate the carbapenemase activity in B. fragilis strains by Carba NP test. In the study, 5.2% of B. fragilis isolates are phenotypically resistant to meropenem. The cfiA gene was identified in 6.1% of B. fragilis isolates. The MICs of meropenem were significantly higher in cfiA-positive strains. The presence of the cfiA gene along with the IS1186 was detected in one B. fragilis strain which was resistant to meropenem (MIC 1.5 mg/L). The Carba NP test results were positive for all the cfiA-positive strains, including those susceptible to carbapenems based on their MIC values. A review of the literature revealed that the rate of B. fragilis with the cfiA gene varies from 7.6 to 38.9% worldwide. Presented results are in line with the other European studies. Phenotypic testing with the Carba NP test, it seems to be a viable alternative for the cfiA gene detection in B. fragilis isolates. The positive result obtained is of greater clinical importance than the detection of the gene cfiA.

脆弱拟杆菌是人类严重感染的重要病原体。需要易于在医学实验室使用的快速方法来检测抗生素耐药性并降低治疗失败的可能性。本研究的目的是确定脆弱拟杆菌 cfi A 阳性分离株的流行率。第二个目的是通过Carba NP试验研究脆弱拟杆菌菌株中碳青霉烯酶的活性。在该研究中，5.2% 的脆弱拟杆菌分离株对美罗培南具有表型耐药性。在 6.1% 的脆弱拟杆菌分离株中发现了cfiA基因。美罗培南的 MIC 在cfi中显着较高A阳性菌株。在一种对美罗培南 (MIC 1.5 mg/L) 具有抗性的脆弱拟杆菌菌株中检​​测到了cfi A 基因和 IS 1186的存在。所有cfi A 阳性菌株的 Carba NP 测试结果均为阳性，包括根据 MIC 值对碳青霉烯类药物敏感的菌株。文献综述显示，全球范围内携带cfi A 基因的脆弱拟杆菌的比例为 7.6% 至 38.9%。所提出的结果与其他欧洲研究一致。使用 Carba NP 测试进行表型测试，它似乎是脆弱拟杆菌中cfi A 基因检测的可行替代方案隔离。所获得的阳性结果比cfi A基因的检测具有更大的临床意义。